Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25344514 | 0.80 | ALDH1A1 (0.39) | NPC1F11 | |
| SCHEMBL6723774 | 0.74 | NPC1 (0.37) | NPC1F11 | |
| SCHEMBL20485581 | 0.73 | NPC1 (0.37) | NPC1 | |
| SCHEMBL1469860 | 0.72 | NPC1 (0.43) | NPC1 | |
| SCHEMBL6722438 | 0.72 | ATM (0.38) | NPC1 | |
| SCHEMBL6730106 | 0.71 | ALDH1A1 (0.39) | NPC1 | |
| SCHEMBL25345868 | 0.70 | MAPT (0.34) | NPC1F11 | |
| SCHEMBL24598999 | 0.70 | NPC1 (0.36) | NPC1 | |
| SCHEMBL31065362 | 0.69 | CYP3A4 (0.52) | NPC1 | |
| SCHEMBL1471386 | 0.69 | NPC1 (0.40) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-05-01 | — | — | US | disclosed |
| EP-4472627-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023150592-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, SLC28A1 | NPC1 465/4885F11 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.